SMMTSummit Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of Summit Therapeutics Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMMTThis | $12.5B#3 | — | 19.9x#13 | — | — | -387.8%#15 | — | -171.4%#14 | — | — | -10.3%#13 | — |
| MRNA | $100.0B#1 | — | 14.8x#10 | 51.4x#3 | -39.9%#6 | 20.8%#5 | -158.1%#3 | -41.7%#11 | -54.6%#3 | — | 955.1%#1 | — |
| TWST | $8.5B#7 | — | 19.1x#12 | 22.6x#1 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#7 | -41.4%#2 | — | 350.7%#4 | — |
| ORKA | $6.4B#10 | — | 5.7x#4 | — | — | -25.9%#7 | — | -9.5%#4 | — | — | 252.3%#5 | — |
| KYMR | $11.0B#4 | — | 6.8x#7 | 280.9x#5 | -16.7%#5 | 39.1%#2 | -891.1%#5 | 19.3%#1 | — | — | 115.3%#8 | — |
| VKTX | $3.4B#14 | — | 5.8x#5 | — | — | -227.1%#14 | — | -61.1%#13 | — | — | -22.7%#15 | — |
| PRAX | $7.8B#8 | — | 5.9x#6 | — | -100.0%#8 | -65.6%#10 | — | -22.6%#9 | — | — | 63.1%#10 | — |
| ERAS | $5.1B#12 | — | 14.0x#9 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | 523.1%#2 | — |
| RVMD | $42.2B#2 | — | 16.2x#11 | — | — | -88.5%#12 | — | -43.4%#12 | — | — | 236.2%#6 | — |
| RYTM | $6.5B#9 | — | 73.6x#14 | 34.1x#2 | 45.8%#3 | 24.6%#3 | -101.2%#2 | -0.2%#3 | -127.5%#4 | — | -11.2%#14 | — |
| CGON | $5.7B#11 | — | 5.6x#3 | 1414.1x#6 | 254.7%#2 | -82.9%#11 | -4722.1%#6 | -15.6%#6 | -18.8%#1 | — | 65.1%#9 | — |
| SLS | $1.8B#15 | — | 13.0x#8 | — | -100.0%#8 | 13.0%#6 | — | -19.5%#8 | — | — | 432.7%#3 | — |
| PCVX | $9.1B#5 | — | 3.3x#1 | — | — | -65.2%#9 | — | -0.0%#2 | — | — | 48.4%#11 | — |
| DNTH | $4.7B#13 | — | 4.0x#2 | 2320.1x#7 | -67.3%#7 | -91.1%#13 | -8739.3%#7 | -13.9%#5 | — | — | 154.1%#7 | — |
| CYTK | $8.9B#6 | — | — | 101.0x#4 | 376.6%#1 | -33.2%#8 | -695.4%#4 | — | — | — | 7.3%#12 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice